Quantcast

Latest Vascular endothelial growth factor Stories

2014-05-31 08:20:45

Phase III data for lenvatinib to be presented at ASCO WOODCLIFF LAKE, N.J., May 31, 2014 /PRNewswire/ -- Eisai Inc. announced today results from the Phase III SELECT trial of investigational agent lenvatinib evaluating progression-free survival (PFS) in patients with progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC). Progression-free survival with lenvatinib was extended significantly compared to placebo (HR=0.21, [99% CI: 0.14-0.31]; p<0.0001). The median...

2014-05-19 08:27:27

ROCKVILLE, Md., May 19, 2014 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced today two poster presentations on ENMD-2076 at the American Society of Clinical Oncology Annual Meeting for two of its trials currently in progress. ENMD-2076 is currently in Phase 2 advanced soft tissue sarcoma and Phase 2 ovarian clear cell carcinoma, trials at Princess Margaret Cancer...

2014-05-15 08:31:37

ROCKVILLE, Md., May 15, 2014 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, today reported financial results for the three months ended March 31, 2014. http://photos.prnewswire.com/prnvar/20010620/ENMDLOGO The Company reported a net loss for the first quarter of 2014 of ($1.5 million), or ($0.05) per share, compared with a net loss of ($1.1 million), or ($0.05) per share,...

2014-05-07 12:26:55

Roche/Genentech's Avastin Continues to Garner the Greatest Physician-Reported Patient Share in DME Due to Its Low Relative Cost, According to Findings from Decision Resources Group BURLINGTON, Mass., May 7, 2014 /PRNewswire/ -- Decision Resources Group finds that, ahead of the anticipated label expansion of Regeneron's Eylea for diabetic macular edema (DME) in August 2014, over half of surveyed U.S. retinal specialists and general ophthalmologists currently prescribe this anti-vascular...

2014-05-07 09:54:08

Mechanisms of VEGF inhibitor-induced hypertension need to be better understood and guidelines developed to improve management, say researchers in the Canadian Journal of Cardiology New cancer therapies, particularly agents that block vascular endothelial growth factor (VEGF) signaling, have improved the outlook for patients with some cancers and are now used as a first line therapy for some tumors. However, almost 100% of patients who take VEGF inhibitors (VEGFIs) develop high blood...

2014-04-24 08:35:50

Renowned ophthalmic expert to provide critical guidance to MacuLogix HUMMELSTOWN, Pa., April 24, 2013 /PRNewswire/ -- MacuLogix, Inc., a pioneer in the early detection and tracking of age-related macular degeneration (AMD), today announced the appointment of Joan W. Miller, MD FARVO as a Clinical Advisor. Dr. Miller will provide MacuLogix with guidance on the development and commercialization of the Company's AdaptDx®, an advanced dark adaptometer used by eye care physicians to...

2014-04-21 20:21:44

INDIANAPOLIS, April 21, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA(TM) (ramucirumab) as a single-agent treatment for patients with advanced or metastatic gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. With this approval, CYRAMZA becomes the first FDA-approved treatment for patients...

2014-04-16 08:32:56

William Greene, MD, Appointed Chief Executive Officer SOUTH SAN FRANCISCO, Calif. and ATLANTA, April 16, 2014 /PRNewswire/ -- Iconic Therapeutics, Inc., a biotechnology company focused on developing therapeutics for serious eye disorders, announced today that it has successfully completed a $20 million Series B-1 equity financing from new investors MPM Capital, Lundbeckfond Ventures, and H.I.G. BioVentures. Iconic's lead clinical-stage program is a novel recombinant human chimeric...

2014-04-03 11:04:31

Scientists at Trinity College Dublin have made a major breakthrough with important implications for sufferers of the eye disease Age-Related Macular Degeneration (AMD), which can cause central blindness in sufferers. The scientists found that a component of the immune system, 'IL-18', acts as a guardian of eyesight by suppressing the production of damaging blood vessels behind the retina at the back of the eye. In addition, in pre-clinical models, it was shown that 'IL-18' can be...

2014-03-26 08:29:46

TORONTO, March 26, 2014 /CNW/ - The Gairdner Foundation is pleased to announce the winners of the 2014 Canada Gairdner Awards, recognizing some of the most significant medical discoveries from around the world. This year's winners showcase a broad range of new medical discoveries related to cardiovascular disease, cancer, immunotherapy and human parasitic diseases. Among the world's most esteemed medical research prizes, the awards distinguish Canada as a leader in science and...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'